Table 1.
Demographic characteristics of patients treated with infliximab for pouch complications.
| Characteristic | Infliximab cohort (n = 42) |
Infliximab responder (n = 26) |
Infliximab non-responder (n = 16) |
p-value |
|---|---|---|---|---|
| Gender (% male) | 25 | 25 | 25 | 0.6 |
| Age at diagnosis (y; median) | 24 | 21 | 25 | 0.3 |
| Age at IPAA (y; median) | 32 | 25 | 33 | 0.1 |
| Pre-treatment CRP (mg/L; mean) | 29 | 20 | 45 | 0.32 |
| Pre-colectomy colitis extent (% with pancolitis) | 85 | 91 | 82 | 0.4 |
| Presence of extra-intestinal manifestations (%) | 29.6 | 60 | 20 | 0.17 |
| Presence of PSC (%) | 0 | 0 | 0 | – |
| Smoking status (% current smokers) | 26 | 16 | 30 | 0.3 |
| Family history of IBD (%) | 14.8 | 16 | 14 | 0.6 |
| Time to surgery from UC diagnosis (y; mean, SD) | 5.2 (4.2) | 3.6 (4.3) | 5.6 (5.0) | 0.2 |
| Time to pouchitis from surgery (y; mean, SD) | 2.1 (3.0) | 2.6 (5.1) | 1.7(3.8) | 0.18 |
| Time from pouchitis to infliximab (y; mean, SD) | 3.1 (4.0) | 2.3(4.1) | 3.9 (5.0) | 0.04* |
| Pre-treatment mPDAI (median; IQR) | 8 (7.5–10.5) | 8 (6–9) | 10 (8–11) | 0.02* |
| CD-like phenotype (%) | 29 | 31 | 25 | 0.5 |
| Pre-colectomy anti-TNF (%) | 74 | 76 | 68 | 0.8 |
| Concomitant immunomodulator (%) | 26 | 31 | 25 | 0.7 |
CD, Crohn’s disease; CRP, C-reactive protein; IBD, inflammatory bowel disease; IPAA, ileal pouch–anal anastomosis; IQR, interquartile range; PSC, primary sclerosing cholangitis; TNF, tumour necrosis factor; UC ulcerative colitis.